GSA Capital Partners LLP Invests $306,000 in Tempus AI, Inc. (NASDAQ:TEM)

GSA Capital Partners LLP acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,408 shares of the company’s stock, valued at approximately $306,000.

Other large investors also recently modified their holdings of the company. Sigma Planning Corp acquired a new stake in shares of Tempus AI during the 3rd quarter worth approximately $1,323,000. Dakota Wealth Management bought a new position in shares of Tempus AI in the 3rd quarter worth $1,185,000. Davidson Kempner Capital Management LP bought a new position in shares of Tempus AI in the 2nd quarter worth $2,271,000. NEA Management Company LLC bought a new position in shares of Tempus AI in the 2nd quarter worth $160,048,000. Finally, Exchange Traded Concepts LLC bought a new position in shares of Tempus AI in the 3rd quarter worth $3,458,000.

Tempus AI Stock Performance

NASDAQ:TEM opened at $58.60 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company’s 50-day moving average price is $51.94.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TEM. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and increased their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital raised their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Piper Sandler restated a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. JPMorgan Chase & Co. raised their price objective on Tempus AI from $42.00 to $47.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Bank of America cut Tempus AI from a “buy” rating to a “neutral” rating and raised their price objective for the company from $45.00 to $60.00 in a research note on Wednesday, October 2nd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average price target of $54.22.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.